With 0.68 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.61 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $15.19 whereas the lowest price it dropped to was $14.45. The 52-week range on BCYC shows that it touched its highest point at $28.67 and its lowest point at $12.17 during that stretch. It currently has a 1-year price target of $33.08. Beta for the stock currently stands at 0.93.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCYC was up-trending over the past week, with a rise of 1.99%, but this was down by -23.44% over a month. Three-month performance dropped to -32.93% while six-month performance fell -26.32%. The stock lost -14.13% in the past year, while it has gained 6.36% so far this year. A look at the trailing 12-month EPS for BCYC yields -3.30 with Next year EPS estimates of -3.53. For the next quarter, that number is -0.85. This implies an EPS growth rate of 40.64% for this year and -17.11% for next year.
Float and Shares Shorts:
At present, 69.02 million BCYC shares are outstanding with a float of 65.57 million shares on hand for trading. On 2024-12-13, short shares totaled 3.43 million, which was 497.0 higher than short shares on 1731628800. In addition to Dr. Kevin Lee M.B.A., Ph.D. as the firm’s CEO & Executive Director, Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE serves as its Co-Founder & Non-Executive Director.
Institutional Ownership:
Through their ownership of 1.0432299 of BCYC’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BCYC reported revenue of $2676000.0 and operating income of -$63527000.0. The EBITDA in the recently reported quarter was -$50772000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCYC since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BCYC analysts setting a high price target of 53.0 and a low target of 17.0, the average target price over the next 12 months is 33.36364. Based on these targets, BCYC could surge 255.94% to reach the target high and rise by 14.17% to reach the target low. Reaching the average price target will result in a growth of 124.07% from current levels.
Analysts have provided yearly estimates in a range of -$2.79783 being high and -$3.41078 being low. For BCYC, this leads to a yearly average estimate of -$3.01533.
